All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2022; the latest 2024-10-18.
From the record
NewAmsterdam Pharma Company N.V.'s filings since 2022 show 1 warning event: a warning not to rely on past financial statements (8-K item 4.02, the latest 2024-10-18) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
-39.7% a year over 4 filed years; profitable in 0 of 4.
From the record
NewAmsterdam Pharma Company N.V.'s 4 filed years say what it did: revenue went from $103 million in fiscal 2022 to $23 million in fiscal 2025, down 39.7% a year; it rose in 1 of 3 years; the deepest fall was 86% from fiscal 2022 to fiscal 2023; net income was positive in 0 of 4 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 2.3/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: NewAmsterdam Pharma Company N.V.'s shareholder treatment is put at 2.3 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 23% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -30%: lost 30¢ per shareholder dollar. Leverage 11%: owes 11¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, NewAmsterdam Pharma Company N.V. lost about 30 cents for every dollar of shareholders' money. Leverage: it owed about 11 cents per dollar of assets, and net share issuance: its share count grew 25.5% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 31% of 315 in its family; net margin -905.7%.
From the record
NewAmsterdam Pharma Company N.V.'s standing among 315 graded names in its industry family: revenue of $23 million in fiscal 2025 ranks in the bottom 48% by size; a net margin of -905.7% ranks in the bottom 31%; revenue growth of -39.7% a year over the last 3 filed years ranks in the bottom 13% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
SI estimate 1.8/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: NewAmsterdam Pharma Company N.V.'s leadership is put at 1.8 of 10 with a confidence of 35 of 100, because read from one part only, officer and director changes on Form 8-K over three years, against the people in charge, which ranks in the bottom 18% of 415 in its family; the record of its people begins on 2023-12-29 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 2.9 years and cannot see past it; a floor under five years is not read as years in charge. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they set up to do next?
How much room does it have to grow?
top 40% of 273 in its family for room to expand.
From the record
NewAmsterdam Pharma Company N.V.'s room to grow, from the newest filed statements (fiscal 2025): cash of $490 million against no long-term debt tagged leaves 63.7% of its assets as net cash, top 26% of its family; cash from operations less capital spending is -657.8% of revenue (bottom 31%); research spending of 630.3% of revenue (top 25%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 46% of 306 in its family for growth drivers.
From the record
NewAmsterdam Pharma Company N.V.'s growth drivers, from the filed years to fiscal 2025: revenue grew -39.7% a year over the last three filed years against -39.7% over all 4, speeding up (top 40% of its family); the newest year grew -50.6% (bottom 16%); research spending grew 17.8% a year (top 26%); capital spending grew 3.6% a year (top 35%) (its annual reports). NewAmsterdam Pharma Company N.V. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 26% of 233 in its family for expectations against reality.
From the record
NewAmsterdam Pharma Company N.V.'s newest year against its own record: revenue of $23 million in fiscal 2025 came in 25.9% below the $30 million its prior three years' pace pointed to (bottom 30% of its family); net income of $204 million against a prior three-year average of $147 million (bottom 29%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 18%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made